Indian scientists develop gene-silencing strategy for breast cancer treatment

Indian scientists have developed a gene-silencing strategy that shows promising results in suppressing breast cancer tumours, offering a potential pathway for next-generation precision nanomedicine, according to India's Ministry of Science and Technology.

Researchers from the Agharkar Research Institute (ARI), an autonomous institute under the Department of Science and Technology (DST), have designed a biodegradable nanocarrier platform for targeted gene therapy in breast cancer.

The study, recently published in Advanced Healthcare Materials, demonstrates how targeted gene silencing can disrupt key survival pathways in breast cancer cells, enabling more effective tumor targeting and suppression.

Scientists said advances in cancer nanomedicine are increasingly focusing on precision approaches that directly target disease-causing genes while reducing harmful side effects associated with conventional treatments.

The researchers believe the new platform could help pave the way for safer and more effective nanomedicine-based therapies for breast cancer by improving the accuracy of drug delivery and minimizing systemic toxicity.